The role of insulin-like growth factor system in soft tissue sarcomas: From physiopathology to targeted therapeutic approaches

Sarcoma

Volumn 2, Issue 2, 1998, Pages 69-76

  Zumkeller, Walter ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Ewing's sarcoma; IGF binding proteins; Insulin like growth factors; Rhabdomyosarcoma; Soft tissue sarcoma; Tumour hypoglycaemia

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; RETINAL; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN RECEPTOR; SURAMIN;

CARCINOGENESIS; DRUG MECHANISM; EWING SARCOMA; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFORMATION; HUMAN; HYPOGLYCEMIA; KIDNEY TUMOR; LEIOMYOMA; LEIOMYOSARCOMA; NEPHROBLASTOMA; NEUROECTODERM TUMOR; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE;

EID: 0031928292     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577149878028     Document Type: Review

References (105)

1. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68:183-223.
2. Wu X, Fan Z, Masui H, et al. Apoptosis induced by blocking epidermal growth factor receptors is rescued by insulin through insulin-like growth factor I receptor. Proc Annu Meet Am Assoc Cancer Res 1994; 35:A16.
3. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 1995; 55:303-6.
4. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985; 313:745-7.
5. Zumkeller W, Schofield PN. Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res 1995; 15:344-8.
6. Zumkeller W, Groth O, Commentz J. Regulation of insulin-like growth factors and IGF-binding proteins in bone tumours. Growth Regul 1996; 6:10-15.
7. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68:183-223.
8. Biran H, Ariel I, de Groot N, et al. Human imprinted genes as oncodevelopmental markers. Tumour Biol 1994; 15:123-34.
9. Rogler CE, Yang D, Rossetti L, et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994; 269:13779-84.
10. Bates P, Fisher R, Ward A, et al. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 1995; 72:1189-93.
11. Sekyi-Otu A, Bell RS, Ohashi C, et al. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res 1995; 55:129-34.
12. Beech D, Pollock RE, Tsan R, et al. Epidermal growth factor receptor and insulin-like growth factor-I receptor expression and function in human soft-tissue sarcoma cells. Int J Oncol 1998; 12:329-36.
13. Sekyi-Otu A, Bell RS, Andrulis IL, et al. Metastatic behaviour of RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. J Natl Cancer Inst 1994; 86:628-32.
14. Höppener J, Mosselman S, Roholl PJ, et al. Expression of insulin-like growth factor I and II genes in human smooth muscle tumours. EMBO J 1988; 7:1379-85.
15. Roholl PJ, Skottner A, Prinsen I, et al. Expression of insulin-like growth factor 1 in sarcomas. Histopathology 1990; 16:455-60.
16. Melhem MF, Meisler AI, Saito R, et al. Cytokines in inflammatory malignant fibrous histiocytoma presenting with leukemoid reaction. Blood 1993; 82:2038-44.
17. Ikejiri K, Wasada T, Haruki K, et al. Identification of a novel transcription unit in the human insulin-like growth factor-II gene. Biochem J 1991; 280:439-44.
18. Gloudemans T, Prinsen I, Van Unnik JAM, et al. Insulin-like growth factor gene expression in human smooth muscle tumours. Cancer Res 1990; 50:6689-95.
19. Holthuizen P, van der Lee FM, Ikejiri K, et al. Identification and initial characterization of a fourth leader exon and promoter of the human IGF-II gene. Biochim Biophys Acta 1990; 1087:341-3.
20. Gloudemans T, Pospiech I, van der Ven LT, et al. Expression and CpG methylation of the insulin-like growth factor II gene in human smooth muscle tumors. Cancer Res 1992; 52:6516-21.
21. Vu TH, Yballe C, Boonyanit S, et al. Insulin-like growth factor II in uterine smooth muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata. J Clin Endocrinol Metab 1995; 80:1670-6.
22. Gloudemans T, Pospiech I, van der Ven LT, et al. An avaII restriction fragment length polymorphism in the insulin-like growth factor II gene and the occurrence of smooth muscle tumors. Cancer Res 1993; 53:5754-8.
23. Tricoli JV, Rall LB, Karakousis CP, et al. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 1986; 46:6169-73.
24. Yee D, Paik S, Lebovic GS, et al. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989; 3:509-17.
25. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 1990; 86:1806-14.
26. Hamilton G, Mallinger R, Hofbauer S, et al. The monoclonal HBA-71 antibody modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor I. Thymus 1991; 18:33-41.
27. Zhan S, Shapiro DN, Helman LJ. Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 1995; 11:2503-7.
28. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996; 56:4570-4.
29. Resnicoff M, Abraham D, Yutanawiboonchai W, et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995; 55:2463-9.
30. Esposito DL, Blakesley VA, Koval AP, et al. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. Endocrinology 1997; 138:2979-88.
31. van Valen F, Winkelmann W, Jürgens H. Type I and II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells. J Cancer Res Clin Oncol 1992; 118:269-75.
32. Hofbauer S, Hamilton G, Theyer G, et al. Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines. Eur J Cancer 1993; 29A:241-5.
33. Shen WP, Towne B, Zadeh TM. Cytogenetic abnormalities in an intraabdominal desmoplastic small cell tumor. Cancer Genet Cytogenet 1993; 64:189-91.
34. Biegel JA, Conard K, Brooks JJ. Translocation (11;22) (p13;q12): primary change in intra-abdominal desmoplastic small round cell tumor. Genes Chromosomes Cancer 1993; 7:119-21.
35. Rauscher FJ III, Benjamin LE, Fredericks WJ, et al. Novel oncogenic mutations in the WT1 Wilms' tumor suppressor gene: a t(11; 22) fuses the Ewing's sarcoma gene, EWS1, to WT1 in desmoplastic small round cell tumor. Cold Spring Harbor Symp Quant Biol 1994; 59:137-46.
36. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 1994; 54:2837-40.
37. Gerald WL, Rosai J, Ladanyi M. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc Natl Acad Sci USA 1995; 92:1028-32.
38. Karnieli E, Werner H, Rauscher FJ 3rd, et al. The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein. J Biol Chem 1996; 271:19304-9.
39. Ouchida M, Ohno T, Fujimura Y, et al. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995; 11:1049-54.
40. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997; 272:30822-7.
41. Gansler T, Gerald W, Anderson G, et al. Characterization of a cell line derived from rhabdoid tumor of the kidney. Hum Pathol 1991; 22:259-66.
42. Sharifah NA, Yun K. Malignant rhabdoid tumor of the kidney expresses insulin-like growth factor II transcripts. Pathology 1994; 26:134-7.
43. Yun K. Clear cell carcinoma of the kidney expresses insulin-like growth factor-II but not WT1 transcripts. Am J Pathol 1993; 142:39-47.
44. Briner J, Hassam S, Rohrer R. Nachweis der unterschiedlichen Expression von IGF-II bei verschiedenen embryonalen Nierentumoren durch slot-blot-Hybridisierung und in-situ-Hybridisierung. Verh Dtsch Ges Pathol 1990; 74:419-23.
45. Zhan S, Helman LJ. Gli the cause of rhabdomyosarcoma. Nature Med 1998; 4:559-60.
46. Kinzler KW, Vogelstein B. The GLI gene encodes a nuclear protein which binds specific sequences in the human genome. Mol Cell Biol 1990; 10:634-42.
47. Hahn H, Wojnowski L, Zimmer AM, et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nature Med 1998; 4:619-22.
48. Pedone PV, Tirabosco R, Cavazzana AO, et al. Mono-and biallelic expression of insulin-like growth factor II gene in human muscle tumors. Hum Mol Genet 1994; 3:1117-21.
49. McCann AH, Miller N, O'Meara A, et al. Biallelic expression of the IGF2 gene in human breast disease. Hum Mol Genet 1996; 5:1123-7.
50. Zhan S, Shapiro D, Zhan S, et al. Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer. J Biol Chem 1995; 270:27983-6.
51. Loh WE Jr, Scrable HJ, Livanos E, et al. Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 1992; 89:1755-9.
52. Scrable H, Cavenee W, Ghavimi F, et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci USA 1989; 86:7480-4.
53. Matsumoto T, Kinoshita E, Maeda H, et al. Molecular analysis of a patient with Beckwith-Wiedemann syndrome, rhabdomyosarcoma and renal cell carcinoma. Jpn J Hum Genet 1994; 39:225-34.
54. Rachmilewitz J, Goshen R, Ariel I, et al. Parental imprinting of the human H19 gene. FEBS Lett 1992; 309:25-8.
55. Rainier S, Johnson LA, Dobry CJ, et al. Relaxation of imprinted genes in human cancer. Nature 1993; 362:747-9.
56. Ariel I, Ayesh S, Perlman EJ, et al. The product of the imprinted H19 gene is an oncofetal RNA. J Clin Pathol: Mol Pathol 1997; 50:34-44.
57. Casola S, Pedone PV, Cavazzana AO, et al. Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene 1997; 14:1503-10.
58. Hao Y, Crenshaw T, Moulton T, et al. Tumour-suppressor activity of H19 RNA. Nature 1993; 365:764-7.
59. Scott J, Cowell JK, Robertson ME, et al. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature 1985; 317:260-2.
60. Gray A, Tam AW, Dull TJ, et al. Tissue-specific and developmentally regulated transcription of the insulin-like growth factor 2 gene. DNA (NY) 1987; 6:283-95.
61. Nielsen FC, Haselbacher G, Christiansen J, et al. Biosynthesis of 10 kDa and 7.5 kDa insulin-like growth factor II in a human rhabdomyosarcoma cell line. Mol Cell Endocrinol 1993; 93:87-95.
62. Gammeltoft S, Christiansen J, Nielsen FC, et al. Insulin-like growth factor II: complexity of biosynthesis and receptor binding. Adv Exp Med Biol 1991; 293:31-44.
63. Nielsen FC, Gammeltoft S, Christiansen J. Translational discrimination of mRNAs coding for human insulin-like growth factor II. J Biol Chem 1990; 265:13431-4.
64. Minniti CP, Helman LJ. IGF-II in the pathogenesis of rhabdomyosarcoma: a prototype of IGFs involvement in human tumorigenesis. Adv Exp Med Biol 1993; 343:327-43.
65. Minniti CP, Tsokos M, Newton WA Jr, et al. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am J Clin Pathol 1994; 101:198-203.
66. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994; 94:445-8.
67. Yun K. A new marker for rhabdomyosarcoma. Insulin-like growth factor II. Lab Invest 1992; 67:653-64.
68. Minniti CP, Luan D, O'Grady C, et al. Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Diff 1995; 6:263-9.
69. El Badry OM, Minniti C, Kohn EC, et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Diff 1990; 1:325-31.
70. Minniti CP, Kohn EC, Grubb JH, et al. The insulin-like growth factor II (IGF/II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells. J Biol Chem 1992; 267:9000-4.
71. Minniti CP, Maggi M, Helman LJ. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res 1992; 52:1830-5.
72. De Giovanni C, Melani C, Nanni P, et al. Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. Br J Cancer 1995; 72:1224-9.
73. Zhang L, Kashanchi F, Zhan Q, et al. Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Res 1996; 56:1367-73.
74. Zhang L, Zhan Q, Zhan S, et al. p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. DNA Cell Biol 1998; 17:125-31.
75. Werner H, Karnieli E, Rauscher FJ, et al. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996; 93:8318-23.
76. Dilling MB, Dias P, Shapiro DN, et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 1994; 54:903-7.
77. cdc2. Cancer Res 1994; 54:5531-4.
78. Shapiro DN, Jones BG, Shapiro LH, et al. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 1994; 94:1235-42.
79. Kalebic T, Blakesley V, Slade C, et al. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer 1998; 76:223-7.
80. Thulasi R, Dias P, Houghton PJ, et al. Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor. Cell Growth Diff 1996; 7:531-41.
81. Crouch GD, Helman LJ. All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. Cancer Res 1991; 51:4882-7.
82. McManus MJ, Hutt PJ, Maihle NJ. Phosphotyrosyl proteins in childhood rhabdomyosarcomas: phosphorylation of catenins and components of the insulin-like growth factor type I receptor signalling cascade. J Pediatr Hematol Oncol 1997; 19:319-26.
83. Zumkeller W, Schwander J, Mitchell CD, et al. Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumour. Eur J Cancer 1993; 29A:1973-7.
84. Müller HL, Oh Y, Lehrnbecher T, et al. Insulin-like growth factor binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 1994; 79:428-34.
85. Romanus JA, Tseng LY, Yang YW, et al. The 34 kilodalton insulin-like growth factor binding proteins in human cerebrospinal fluid and the A673 rhabdomyosarcoma cell line are human homologues of the rat BRL-3A binding protein. Biochem Biophys Res Commun 1989; 163:875-81.
86. Koscielniak EB, Gutbrod R, Blum W, et al. Varying patterns of secretion of insulin-like growth factors (IGFs) and their binding proteins (BPs) by sarcoma cell lines. Proc Am Assoc Cancer Res. 1994; 35:44.
87. van der Ven LT, van Buul-Offers SC, Gloudemans T, et al. Modulation of insulin-like growth factor (IGF) action by IGF-binding proteins in normal, benign, and malignant smooth muscle tissues. J Clin Endocrinol Metab 1996; 81:3629-35.
88. Lowe WL Jr, Roberts CT Jr, LeRoith D, et al. Insulin-like growth factor-II in nonislet cell tumors associated with hypoglycemia: increased levels of messenger ribonucleic acid. J Clin Endocrinol Metab 1989; 69:1153-9.
89. Schofield PN, Nyström A, Smith J, et al. Expression of a high molecular weight form of insulin-like growth factor II in a Beckwith-Wiedemann syndrome associated adrenocortical adenoma. Cancer Lett 1995; 94:71-7.
90. Daughaday WH, Trivedi B, Baxter RC. Serum 'big insulin-like growth factor II' from patients with turnor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing. Proc Natl Acad Sci USA 1993; 90:5823-7.
91. Daughaday WH, Emanuele MA, Brooks MH, et al. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med 1988; 319:1434-40.
92. Chung J, Henry RR. Mechanisms of tumor-induced hypoglycemia with intraabdominal hemangiopericytoma. J Clin Endocrinol Metab 1996; 81:919-25.
93. Höög A, Sandberg-Nordqvist AC, Hulting AL, et al. High molecular weight IGF-2 expression in a haemangiopericytoma associated with hypoglycemia. APMIS 1997; 105:469-82.
94. Cotterill AM, Holly JM, Davies SC, et al. The insulin-like growth factors and their binding proteins in a case of non-islet-cell tumour-associated hypoglycaemia. J Endocrinol 1991; 131:303-11.
95. Wegmann W, Vonesch HJ, Kamber J, et al. Rezidivierendes und metastasierendes Hämangioperizytom der Meningen mit paraneoplastischer Hypoglykämie. Schweiz Med Wochenschr 1994; 124:146-51.
96. Sohda T, Yun K. Insulin-like growth factor II expression in primary meningeal hemangiopericytoma and its metastasis to the liver accompanied by hypoglycemia. Hum Pathol 1996; 27:858-61.
97. Trivedi N, Mithal A, Sharma AK, et al. Non-islet cell tumour induced hypoglycemia with acromegaloid facial and acral swelling. Clin Endocrinol 1995; 42:433-5.
98. Kotani K, Tsuji M, Oki A, et al. IGF-II producing hepatic fibrosarcoma associated with hypoglycemia. Intern Med 1993; 32:897-901.
99. Wasada T, Hizuka N, Yamamoto M, et al. An insulin-like growth factor II-producing histiocytoma associated with hypoglycemia: analysis of the peptide, its gene expression, and glucose transporter isoforms. Metabolism 1992; 41:310-6.
100. Schofield PN, Connor H, Turner RC, et al. Tumour hypoglycaemia: raised tumour IGFII mRNA associated with reduced plasma somatomedin. Br J Cancer 1989; 60:661-3.
101. Daughaday WH, Kapadia M. Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proc Natl Acad Sci USA 1989; 86:6778-82.
102. Baxter RC. The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia. Horm Res 1996; 46:195-201.
103. Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to non-islet cell tumors. J Clin Endocrinol Metab 1991; 73:696-702.
104. Baxter RC, Holman SR, Corbould A, et al. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 1995; 80:2700-8.
105. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55:249-52.